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64Objectives: Transcatheter aortic valve implantation (TAVI) has recently been advocated to decrease perioper-
ative risk in high-risk patients. In this propensity-score analysis we compared outcomes after TAVI to those after
surgical aortic valve replacement (AVR).
Methods: From June 2009 through June 2010, 82 consecutive patients underwent TAVI via a transapical
(n¼ 60) or transfemoral (n¼ 22) approach using the Edwards Sapien prosthesis (Edwards Lifesciences, Irvine,
Calif). Mean patient age was 81.9  5.2 years, 64.6% were women. Logistic EuroSCORE was 23.6%  1.4%
and Society of Thoracic Surgeons score was 8.7%  1.3%. A group of 82 patients after surgical AVR was
retrieved from our database, yielding a control group that was matched to the cases with respect to baseline
demographics and typical risk factors.
Results:Overall mortality did not differ significantly between TAVI andAVR groups at 30 days (7.3% vs 8.6%),
90 days (13.6% vs 11.1%), or 180 days (17.8% vs 16.9%; P ¼ .889). Conversion to surgery was necessary in
2 (2.4%) TAVI cases. Perioperative stroke occurred in 2 (2.4%) cases per group. Pacemakers were implanted for
new-onset heart block in 3.7% and 2.4% in the TAVI and AVR groups, respectively (P¼ 1.0). TAVI resulted in
shorter operative times (P<.001), shorter ventilation times (P<.001), and shorter length of stay in the intensive
care unit (P ¼ .008). Duration of hospital stay, however, was not significantly different (P ¼ .11).
Conclusions: In our experience, mortality rates are similar after both types of procedure. Patients receiving
TAVI benefit from faster postoperative recovery. Until more clinical data become available, the optimal proce-
dure has to be determined for each patient according to individual risk factors. (J Thorac Cardiovasc Surg
2012;143:64-71)Calcific aortic stenosis is a progressive and irreversible con-
dition with a dismal prognosis if left untreated. Until re-
cently, surgical substitution of the native valve by
a biological or mechanical heart valve prosthesis was the
only durable treatment option. Surgical aortic valve re-
placement (AVR) can be performed in a highly standardized
manner with low perioperative morbidity and mortality
even in octogenarians.1-4 or patients deemed at high
surgical risk5 and has to serve as the clinical benchmark
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The Journal of Thoracic and Cardiovascular Surgesymptoms and results in improved quality of life and excel-
lent short- and long-term survival. Owing to the low perio-
perative morbidity, AVR may be indicated even in
asymptomatic patients with severe aortic stenosis.6 How-
ever, it is a clinical reality that a substantial share of patients
are denied surgery as a result of presumed or real contrain-
dications or because operative risk is deemed prohibitively
high owing to comorbidities.7 It is for this growing popula-
tion of high-risk patients that less invasive, beating-heart
transarterial retrograde or transapical antegrade aortic valve
implantation (TAVI) procedures have been developed and
introduced into clinical practice for primary valve implanta-
tion,8,9 in combination with percutaneous coronary
interventions10 or even for redo valve-in-valve proce-
dures.11 In this study, outcomes of a cohort of 82 consecu-
tive TAVI procedures were analyzed and compared with
a propensity-adjusted control group of patients after surgi-
cal AVR.PATIENTS AND METHODS
From June 2009 through June 2010, 82 consecutive patients with severe
aortic stenosis underwent TAVI via a transapical (n ¼ 60) or transfemoral
approach (n ¼ 22) using the Edwards Sapien balloon expandablery c January 2012
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
LVEF ¼ left ventricular ejection fraction
NYHA ¼ New York Heart Association
PARTNER ¼ Placement of AoRTic
TraNscathetER Valve (trial)
PPM ¼ patient–prosthesis mismatch
TAVI ¼ transapical antegrade aortic valve
implantation
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Dpericardial xenograft (Edwards Lifesciences, Irvine, Calif). Decision-
making for TAVI or AVR was a formal process involving a dedicated
interdisciplinary heart team of cardiac surgeons, interventional and
noninterventional cardiologists, cardiac anesthetists, and intensive care
physicians. All patients with elevated risk were discussed in an interdisci-
plinary conference and were allocated to one or the other treatment option
only by mutual agreement. All TAVI procedures were performed by the
heart team in a hybrid operating theater. Transesophageal echocardiogra-
phy and fluoroscopy were used to guide the implantation procedure.
TAVI was performed in a standard manner as described previously.12 Pa-
tients considered eligible for TAVI were generally older than 75 years of
age although age alone did not qualify as a single criterion for TAVI. All
patients were considered to be at high surgical risk owing to comorbidities
with a logistic EuroSCORE of 20% or greater.
Patients deemed poor surgical candidates, were primarily evaluated for
a transfemoral approach and allocated to a transapical procedure in case of
severe aortoiliac disease or peripheral vessels otherwise unsuitable for
transfemoral access. Special consideration was given to sclerosis of the aor-
tic arch, which when present led to a liberal indication of transapical pro-
cedures to avoid potential mobilization and embolism of atheroma. Owing
to their age and cardiovascular risk profile, sclerosis of the aortic arch is
common in the typical TAVI population, leading to a transapical/transfe-
moral ratio of 2:1 in our overall experience. To derive a surgical control
group, we identified 499 patients aged 75 years or older from the hospital
records out of a total of 1656 patients treated by isolated AVR for aortic
stenosis between 2001 and 2009 at our center. From these, 82 patients
were extracted by means of propensity scoring regarding the following var-
iables: age, gender distribution, logistic EuroSCORE, Society of Thoracic
Surgeons Predicted Risk of Mortality, New York Heart Association
(NYHA) functional class, left ventricular ejection fraction (LVEF), moder-
ate reduction of LVEF (30%-50%), severe reduction of LVEF (<30%),
prior stroke, cerebrovascular disease, peripheral artery disease, coronary
artery disease, creatinine, diabetes, arterial hypertension, pulmonary hy-
pertension greater than 60 mm Hg, chronic obstructive pulmonary disease
greater than or equal to Global Initiative for Chronic Obstructive Lung Dis-
ease II, malignant disease, previous cardiac surgery, atrial fibrillation, and
prior pacemaker implantation. Patients were followed up to 180 days
after the procedure. Patient data of the 2 respective cohorts are detailed
in Table 1.
Statistical Analysis
Data are presented as absolute numbers and percentages for categorical
variables and mean values and standard deviations for continuous vari-
ables. Dichotomous variables were compared using Fisher’s exact test
and continuous variables by t tests. In case of trends for categorical vari-
ables, we used the Cochran-Armitage trend test. Kaplan-Meier analysis
and log–rank test were used for time-to event analyses. P values are re-
ported without correction for multiple testing. A logistic regression model
was used to generate a surgical control group matched for the variablesThe Journal of Thoracic and Cdetailed above. All statistical analysis was performed using SPSS 19.0 or
the statistical package R version 2.12.2 (SPSS, Inc, Chicago, Ill).RESULTS
Periprocedural Results to 30 Days
In the TAVI group, procedural success with deployment
of a functional prosthesis was achieved in 79 (96.3%) pa-
tients. In 2 (2.4%) patients, conversion to surgery and car-
diopulmonary bypass became necessary for dislocation of
the prosthesis into the left ventricular outflow tract in 1 pa-
tient and apical rupture in another. In the surgical group,
valve implantation was successful in all cases. Operative
times differed significantly between the 2 groups: TAVI
128.9  9.0 minutes versus AVR 200.9  7.6 minutes
(P ¼ .04). There were no intraoperative deaths in the
AVR cohort. Two patients in the TAVI cohort died during
the procedure (2.4%), 1 patient owing to a Stanford type
A aortic dissection after transfemoral TAVI and 1 patient
owing to apical rupture after a transapical procedure. Addi-
tional intraoperative data are summarized in Table 2.
In the TAVI cohort, 59 (72.0%) patients were extubated
in the operating room immediately after the procedure.
Mean ventilation times (P< .001) and mean duration of
stay in the intensive care unit (P ¼ .008) were significantly
shorter in the TAVI group. Postoperative bleeding (P¼ .07)
and transfusion requirements (P<.001) were also lower in
TAVI patients than in the surgical control group. Pacemaker
implantation for new-onset total atrioventricular block be-
came necessary in 3 (3.7%) TAVI patients and in 2
(2.4%) patients from the surgical cohort. Two (2.4%)
strokes occurred in each cohort; in the TAVI cohort, 1 stroke
occurred after a transfemoral and 1 after a transapical pro-
cedure. Echocardiography at discharge revealed good
hemodynamic function of the implanted valves. Transvalv-
ular pressure gradients were comparable between the 2 co-
horts, whereas mean grade of paravalvular leakage was
higher in the TAVI cohort (P<.001). In the TAVI cohort,
50% (n ¼ 41) of patients had some degree of paravalvular
leakage, which was trivial to mild in 40 patients and mod-
erate in 1 patient. In the surgical cohort, no paravalvular
leakage was observed in any patient. Postoperative trans-
valvular aortic regurgitation was present in 25.6%
(n¼ 21) of surgical patients and it was trivial in all of these
cases. Severe patient–prosthesis mismatch (PPM, defined as
an indexed effective orifice area of 0.65) or less, was present
in 10 (12.2%) TAVI patients. Two of these patients died
during follow-up, 1 patient of cancer 260 days after the pro-
cedure and another patient of heart failure 160 days after the
procedure. In the AVR cohort, severe PPM was present in
1 (1.2%) patient who died on postoperative day 291 after
an acute myocardial infarction.
In the present series, 42 (51.2%) TAVI patients had cor-
onary artery disease. In 13 (15.9%) patients, coronary ar-
tery disease was treated by percutaneous coronaryardiovascular Surgery c Volume 143, Number 1 65
TABLE 1. Baseline demographics and risk factors for the TAVI and the AVR cohorts in the study population
TAVI AVR P value
n 82 82
Age (y) 81.9  5.2 82.5  4.1 .39
Female gender 52 (63.4%) 48 (58.5%) .52
LogEuroSCORE (%) 23.9  11.5 23.6  10.4 .85
STS-PROM (%) 8.5  1.3 9.0  4.9 .74
NYHA functional class 3.1  0.6 3.2  0.6 .15
NYHA I 1 (1.2%) 0 1.0
NYHA II 7 (8.5%) 5 (6.1%) .77
NYHA III 57 (69.5%) 46 (56.1%) .11
NYHA IV 13 (15.9%) 19 (23.2%) .32
LVEF (%) 52.5  8.4 50.6  10.7 .23
LVEF 30%-50% 18 (22.0%) 22 (26.8%) .85
LVEF<30% 3 (3.7%) 8 (9.8%) .21
Mean EOA (cm2) 0.7  0.2 0.6  0.1 .02
Peak/mean gradient (mm Hg) 39.2  16.3/65.0  24.9 45.8  16.7/75.3  25.5 .02/.01
Prior stroke or TIA 16 (19.5%) 14 (17.1%) .84
Cerebrovascular disease 19 (23.2%) 18 (22.0%) 1.00
Coronary artery disease 42 (51.2%) 35 (42.7%) .35
Peripheral artery disease>Fontaine II (%) 16 (19.5%) 12 (14.6%) .53
Porcelain aorta (%) 2 (2.4%) 0 .50
Creatinine (mg/dL) 1.4  1.2 1.3  0.5 .44
Creatinine>1.8 mg/dL (%) 10 (12.2%) 7 (8.5%) .46
Diabetes (%) 28 (34.2%) 25 (30.5%) .74
Arterial hypertension (%) 68 (82.9%) 73 (89.0%) .27
Pulmonary hypertension>60 mm Hg (%) 14 (17.0%) 20 (24.4%) .34
COPD  GOLD II (%) 24 (29.3%) 27 (32.9%) .74
Malignant disease (%) 7 (8.5%) 2 (2.4%) .17
Previous cardiac surgery (%) 20 (24.4%) 11 (13.4%) .11
Atrial fibrillation (%) 25 (30.5%) 35 (42.7%) .14
Prior pacemaker implantation (%) 6 (7.3%) 5 (6.1%) 1.00
n (%) listed for categorical variables. TAVI, Transapical antegrade aortic valve implantation; AVR, aortic valve replacement; LogEuroSCORE, logistic European system for car-
diac operative risk evaluation; STS-PROM, Society of Thoracic Surgeons Predicted Risk of Mortality; NYHA,NewYork Heart Association functional class; LVEF, left ventricular
ejection fraction; EOA, effective orifice area; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive
Lung Disease.
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Dintervention either as a staged approach at 11.9  9.6 days
before TAVI (n ¼ 10) or as a single-stage procedure imme-
diately before TAVI (n ¼ 3). Percutaneous coronary inter-
vention was performed with a mean of 1.7  1.5 stents
and a total stent length of 23.0  20.1 mm using bare metal
stents in 6 cases and drug-eluting stents in 7 cases.
Mortality rates at 30 days did not differ significantly be-
tween TAVI (n ¼ 6, 7.3%) and AVR cohorts (n ¼ 7, 8.6%;
P ¼ 1.0). For greater detail of acute clinical and hemody-
namic outcomes, see Table 3.
Follow-up Data
During further follow-up, overall mortality rates were
similar for the 2 patient cohorts. For TAVI and AVR, mor-
tality rates were 13.6% and 11.1% (P ¼ 0.8) at 90 days
and 17.8% and 16.9% (P ¼ 1.0) at 180 days (Figure 1).
Whereas the majority of deaths during the 30-day follow-
up were procedure related (84.6%) in both cohorts, late
mortality was mostly related to the patients’ comorbidities.66 The Journal of Thoracic and Cardiovascular SurgeFrom 21 (25.6%) patients in the TAVI cohort with an LVEF
of 50% or less, 4 died during follow-up, resulting in a mor-
tality rate of 19.0%, which is insignificantly higher than the
17.1% in the overall TAVI cohort (P ¼ .76). Furthermore,
from 41 (50%) TAVI patients with any degree of paravalv-
ular leakage, aortic regurgitation was graded as mild in 8
and as moderate in 1 patient. Among 9 patients with mild
or moderate paravalvular leakage, 1 (11.1%) death oc-
curred at 5 months after the procedure.
Major adverse cardiac and cerebrovascular event rates
were also comparable between the 2 groups. Incidence of
major adverse cardiac and cerebrovascular events (death,
stroke, myocardial infarction, or reoperation) for TAVI
and AVR was 16.1% and 13.5% (P ¼ .83) at 90 days and
21.7% and 19.1% (P ¼.84) at 180 days (Figure 2). In
both groups there were no myocardial infarctions or reoper-
ations during 180 days of follow-up. Clinically, patients im-
proved markedly during the further postoperative course.
Preoperatively, the majority of all patients had been inry c January 2012
TABLE 2. Intraoperative data
TAVI
(n ¼ 82)
AVR
(n ¼ 82)
P
value
Procedure time (min) 128.9  9.0 200.9  58.1 <.0001
Cardiopulmonary bypass (min) n/a 111.0  36.2 —
Aortic crossclamp time (min) n/a 70.8  23.2 —
Fluoroscopy time (min) 9.8  8.5 n/a —
Contrast agent (mL) 198.3  93.1 n/a —
Valve size (mm) 24.3  1.7 22.2  1.8 <.0001
19 mm n/a 7 (8.5%) —
21 mm n/a 33 (40.2%) —
23 mm 49 (59.8%) 31 (37.8%) —
25 mm n/a 7 (8.5%) —
26 mm 30 (36.6%) — —
27 mm n/a 4 (4.9%) —
29 mm 3 (3.7%) — —
Procedural success (%) 79 (96.3%) 82 (100.0%) .25
Conversion to surgery (%) 2 (2.4%) — —
Intraprocedural death (%) 2 (2.4%) 0 .50
n (%) listed for categorical variables. TAVI, Transapical antegrade aortic valve im-
plantation; AVR, aortic valve replacement; n/a, not available.
TABLE 3. Acute postoperative results and complications
TAVI
(n ¼ 82)
AVR
(n ¼ 82)
P
value
Ventilation time (min) 5.1  20.6 19.9  14.7 <.001
Patients extubated in OR 59 (72.0%) 0 <.001
Duration of ICU stay (d) 2.5  2.2 3.8  3.3 .008
Duration of hospital stay (d) 13.5  13.1 10.6  7.7 .11
Mean gradient at discharge
(mm Hg)
11.3  5.6 11.8  5.3 .62
19 mm n/a 8.8  5.1 —
21 mm n/a 12.9  4.7 —
23 mm 11.8  6.2 12.7  5.9 —
25 mm n/a 7.6  3.4 —
26 mm 10.5  4.3 n/a —
27 mm n/a 10.8  6.0 —
29 mm 5.3  1.2 n/a —
Peak gradient at discharge
(mm Hg)
21.5  10.0 22.9  10.1 .41
Paravalvular aortic
regurgitation (grade)
0.8  0.7 0 <.001
Total amount of bleeding
(mL)
521.1  844.1 888.6  1477.3 .07
Transfusion (units PRBC) 0.1  0.6 1.8  1.7 <.001
Patients receiving transfusion 6 (7.3%) 53 (64.6%) <.001
Impaired wound healing 5 (6.1%) 3 (3.7%) .72
Pacemaker implantation (%) 3 (3.7%) 2 (2.4%) 1.00
Stroke to 30 days 2 (2.4%) 2 (2.4%) 1.00
Thirty-day mortality (%) 6 (7.3%) 7 (8.6%) 1.00
n (%) listed for categorical variables. TAVI, Transapical antegrade aortic valve im-
plantation; AVR, aortic valve replacement; OR, operating room; ICU, intensive care
unit; PRBC, packed red blood cells; n/a, not available.
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DNYHA functional class III (62.8%) or IV (19.5%) with
mean NYHA of 3.1  0.6 and 3.2  0.6 for TAVI and
AVR, respectively. Postoperatively, marked improvement
in patients’ NYHA class was noted in both cohorts and
this effect remained stable to the latest follow-up. At 30
days, 73.2% (n ¼ 120) of patients had improved by 1 or
more NYHA classes. At 180 days postoperatively, mean
NYHA class was 2.2  0.8 and 2.3  1.0 for TAVI and
AVR, respectively.FIGURE 1. Kaplan-Meier survival curves for patients receiving TAVI
compared to a surgical control group after AVR. During a follow-up of
180 days, no statistically significant differences were noted. TAVI, Transap-
ical antegrade aortic valve implantation; AVR, aortic valve replacement.DISCUSSION
TAVI has become the treatment of choice at many centers
for patients with severe aortic stenosis and no surgical op-
tions owing to exceedingly high operative risk. As recently
shown in the multicenter prospective randomized Place-
ment of AoRTic TraNscathetER Valve (PARTNER) trial,
TAVI is effective in reducing all-cause mortality in patients
with inoperable conditions compared with best medical
therapy.13 Furthermore, TAVI has been advocated to de-
crease operative morbidity and mortality in patients at
high surgical risk inasmuch as it eliminates the need for me-
dian sternotomy, cardiopulmonary bypass, and aortic cross-
clamping with their respective inherent risks. However, to
date little evidence exists on the effectiveness of TAVI com-
pared with surgical AVR as the reference treatment for aor-
tic stenosis. In 2009, Zierer and coworkers14 presented
a study on their initial experience in 21 patients undergoing
transapical TAVI and compared outcomes to a matched
group of 30 patients after minimally invasive surgical
AVR via a partial upper sternotomy. They found that
TAVI resulted in faster postoperative recovery, for example,
shorter postoperative ventilation times and shorter durationThe Journal of Thoracic and Cof intensive care unit and overall hospital stay. Regarding
acute and 1-year mortality, no statistically significant differ-
ences were observed, although there was a trend toward
more favorable outcome in the surgical group. However,
since the initial TAVI experience was compared with an
established concept of minimally invasive AVR, thisardiovascular Surgery c Volume 143, Number 1 67
FIGURE 2. Kaplan-Meier analysis for survival free of major adverse
cardiac and cerebrovascular events (ie, death, stroke, acute myocardial in-
farction, reoperation). Event rates were similar between the 2 cohorts.
TAVI, Transapical antegrade aortic valve implantation; AVR, aortic valve
replacement.
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D observation may at least in part result from the learning
curve associated with any new surgical procedure.
In another study, 100 consecutive transapical TAVI pro-
cedures were compared with 100 propensity-score matched
cases of surgical AVR. Patients undergoing TAVI had a sig-
nificantly higher likelihood to be managed without any
intensive care unit stay postoperatively and benefited from
an insignificantly lower stroke rate than surgical candidates.
Mortality rates were not different between the 2
approaches.15
In the present study, we present the results from a single-
center, real world experience with outcomes after 82 con-
secutive transfemoral or transapical TAVI procedures using
the Edwards Sapien heart valve. The results from both the
transcatheter and the surgical control group seem accept-
able, particularly when considering the high surgical risk
of the study population. Similar to the 2 previous stud-
ies,14,15 we found significant advantages for patients
undergoing TAVI regarding ventilation time and duration
of stay in the intensive care unit, suggesting faster
postoperative recovery when compared with patients after
AVR. However, this did not translate into shorter overall
duration of hospital stay in the TAVI cohort, mostly
owing to the fact that TAVI patients were kept under
continuous electrocardiographic surveillance for an
extended period after the procedure for detection of late
occurrence of conduction disorders.
Furthermore, lower transfusion requirements were noted
in the TAVI cohort. There was a significantly higher mean
grade of postoperative aortic regurgitation in the TAVI co-
hort. Fifty percent of patients had some degree of paravalv-
ular leakage, which was trivial or mild in all but 1 patient.
The latter, however, had an uneventful clinical course, and
no signs of hemolysis were observed in any patient. Neither
impaired left ventricular function nor grade of paravalvular68 The Journal of Thoracic and Cardiovascular Surgeleakage had a negative impact on patient outcome in our
series.
Even though mean valve size was significantly larger in
the TAVI cohort, postprocedural peak and mean transvalv-
ular gradients were similar compared with the AVR cohort.
Possibly, this is at least in part due to incomplete expansion
of TAVI prostheses, especially in patients with heavily cal-
cified valve cusps. Correspondingly, severe PPM was pres-
ent in 10 (12.2%) TAVI patients but only in 1 (1.2%) AVR
patient. However, in this population of elderly, comorbid
patients, PPM did not seem to influence survival during
a follow-up of 180 days.
In our experience, operative mortality was lower than
predicted by logistic EuroSCORE, even though the Euro-
SCORE is known to overestimate operative risk especially
in these high-risk patients.16 Furthermore, adequateness of
standard surgical risk stratification tools for the evaluation
of risks inherent in TAVI procedures remains controver-
sial.17 Regarding mortality, no significant differences
were found between the 2 respective cohorts in our experi-
ence. Overall 30- and 180-day mortality rates correspond to
those reported from other European single-center experi-
ences or national registries.15,18-21
To date, results from only 1 prospective randomized trial
exist comparing outcomes after TAVI and surgical AVR in
high-risk patients. Data of the PARTNER Trial Cohort A
were recently published.22 Patients were randomized to re-
ceive either transfemoral or transapical TAVI (n ¼ 348) or
surgical AVR (n¼ 351). The primary end point of the study
was all-cause mortality at 1 year; secondary end points in-
cluded safety and clinical effectiveness issues. Overall 30-
day mortality was 3.4% in the TAVI cohort, which is the
lowest reported in any TAVI series to date, compared with
6.5% in the surgical cohort (P ¼ .07). Exclusion criteria
as defined in the study protocol, such as severely reduced
left ventricular function (LVEF<20%) or severe renal dys-
function (serum creatinine>3.0 mg/dL or dialysis depen-
dent), may have contributed to this difference when
compared with the European experience.
After 1 year, mortality was 24.2% in the TAVI cohort
versus 26.8% in the surgical cohort, meeting the noninfer-
iority hypothesis (P ¼ .001). The study investigators con-
clude that TAVI is an acceptable alternative to surgical
AVR for selected high-risk patients.
CONCLUSIONS
In conclusion, our results and the results of other obser-
vational trials, as well as the randomized PARTNER trial,
suggest the decision for TAVI or AVR for treatment of aortic
stenosis in high-risk patients has to be based on clinical
judgment and on the individual patient’s characteristics
and risk factors. At present, TAVI and AVR seem to be com-
plementary approaches for treatment of high-risk patients
with severe aortic stenosis and permit a patient-orientated,ry c January 2012
Conradi et al Acquired Cardiovascular Diseasetailor-made treatment strategy. Decision for one or the other
treatment option should be made within a heart center by an
interdisciplinary dedicated heart valve team including car-
diologists, cardiac surgeons, cardiac anesthetists, and inten-
sive care physicians and should be independent from any
financial or budget-related bias. It seems likely that with
technical refinement of existing devices and mounting clin-
ical experience of implanting physicians, further improve-
ment of clinical outcome after TAVI can be anticipated.
The question whether this development will justify exten-
sion of the technique to patients with a lower risk profile
cannot be answered at present and warrants the conductance
of further randomized trials.A
C
DLimitations
The present study did not randomize patients to receive
either TAVI or AVR. Therefore, unknown and potentially
confounding variables may have had an impact on out-
comes. However, risk adjustment yielded 2 patient cohorts
that were similar regarding many baseline demographics
and risk factors. The retrospective nature and limited patient
number in this study are further potential limitations.References
1. Gummert JF, Funkat A, Beckmann A, Schiller W, Hekmat K, Ernst M, et al. Car-
diac surgery inGermany during 2006: a report on behalf of theGermanSociety for
Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surg. 2007;1:343-50.
2. Bose AK, Aitchison JD, Dark JH. Aortic valve replacement in octogenarians. J
Cardiothorac Surg. 2007;2:33.
3. Melby SJ, Zierer A, Kaiser SP, Guthrie TJ, Keune JD, Schuessler RB, et al. Aor-
tic valve replacement in octogenarians: risk factors for early and late mortality.
Ann Thorac Surg. 2007;83:1651-6.
4. Sundt T, Bailey MS, Moon MR, Mendeloff EN, Huddleston CB, Pasque MK,
et al. Quality of life after aortic valve replacement at the age of>80 years. Cir-
culation. 2000;102(19 Suppl. 3):III70-4.
5. Thourani VH, Ailawadi G, Szeto WY, Dewey TM, Guyton RA, Mack MJ, et al.
Outcomes of surgical aortic valve replacement in high-risk patients: a multiinsti-
tutional study. Ann Thorac Surg. 2011;91:49-56.
6. BrownML, Pellikka PA, Schaff HV, Scott CG, Mullany CJ, Sundt TM, et al. The
benefits of early valve replacement in asymptomatic patients with severe aortic
stenosis. J Thorac Cardiovasc Surg. 2008;135:308-15.
7. Iung B, Cachier A, Baron G, Messika-Zeitoun D, Delahaye F, Tornos P. Deci-
sion-making in elderly patients with severe aortic stenosis: why are so many de-
nied surgery? Eur Heart J. 2005;26:2714-20.
8. Webb JG, Pasupati S, Humphries K, Thompson C, Altwegg L, Moss R, et al. Per-
cutaneous transarterial aortic valve replacement in selected high-risk patients
with aortic stenosis. Circulation. 2007;116:755-63.
9. Walther T, Simon P, Dewey T, Wimmer-Greinecker G, Falk V, Kasimir MT, et al.
Transapical minimally invasive aortic valve implantation: multicenter experi-
ence. Circulation. 2007;116(11 Suppl):I240-5.
10. Conradi L, Seiffert M, Franzen O, Baldus S, Schirmer J, Meinertz T, et al. First
experience with transcatheter aortic valve implantation and concomitant percuta-
neous coronary intervention. Clin Res Cardiol. 2011;100:311-6.
11. Seiffert M, Franzen O, Conradi L, Baldus S, Schirmer J, Meinertz T, et al. Series
of transcatheter valve-in-valve implantations in high-risk patients with degener-
ated bioprostheses in aortic and mitral position.Cath Cardiovasc Interv. 2010;76:
608-15.
12. Conradi L, Treede H, Franzen O, Seiffert M, Baldus S, Schirmer J, et al. Trans-
catheter aortic and mitral valve interventions: update 2010. Interv Cardiol. 2010;
2:513-23.
13. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Trans-
catheter aortic-valve implantation for aortic stenosis in patients who cannot un-
dergo surgery. N Engl J Med. 2010;363:1597-607.The Journal of Thoracic and C14. Zierer A, Wimmer-Greinecker G, Martens S, Moritz A, Doss M. Is transapical
aortic valve implantation really less invasive than minimally invasive aortic valve
replacement? J Thorac Cardiovasc Surg. 2009;138:1067-72.
15. Walther T, Schuler G, Borger MA, Kempfert J, Seeburger J, R€uckert Y, et al.
Transapical aortic valve implantation in 100 consecutive patients: comparison
to propensity-matched conventional aortic valve replacement. Eur Heart J.
2010;31:1398-403.
16. Rosenhek R, Iung B, Tornos P, Antunes MJ, Prendergast BD, Otto CM, et al. ESC
working group on valvular heart disease position paper: assessing the risk of in-
terventions in patients with valvular heart disease. Eur Heart J. 2011 Mar 15
[Epub ahead of print].
17. Mack MJ. Risk scores for predicting outcomes in valvular heart disease. How
useful? Curr Cardiol Rep. 2011;13:107-12.
18. Elhmidi Y, Bleiziffer S, Piazza N, Hutter A, Opitz A, Hettich I, et al. Incidence
and predictors of acute kidney injury in patients undergoing transcatheter aortic
valve implantation. Am Heart J. 2011;161:735-9.
19. Bosmans JM, Kefer J, De Bruyne B, Herijgers P, Dubois C, Legrand V, et al. Pro-
cedural, 30-day and one year outcome following CoreValve or Edwards trans-
catheter aortic valve implantation: results of the Belgian national registry.
Interact Cardiovasc Thorac Surg. 2011 Feb 24 [Epub ahead of print].
20. Figulla L, Neumann A, Figulla HR, Kahlert P, Erbel R, Neumann T. Transcath-
eter aortic valve implantation: evidence on safety and efficacy compared with
medical therapy. A systematic review of current literature. Clin Res Cardiol.
2011;100:265-76.
21. Seiffert M, Treede H, Franzen O, Conradi L, Schimer J, Baldus S, et al. Mortality
after transapical aortic valve implantation is not related to the procedure but to the
preoperative risk. Thorac Cardiovasc Surg. 2010;58(Suppl.1):S116.
22. Smith CR, LeonMB,MackMJ,Miller DC,Moses JW, Svensson LG, et al. Trans-
catheter versus surgical aortic-valve replacement in high-risk patients. N Engl J
Med. 2011;364:2187-98.Discussion
Dr Vinod H. Thourani (Atlanta, Ga).My disclosure is I am an
investigator and on the steering committee for the Edwards PART-
NER trial. I appreciate the opportunity to discuss this important
and timely paper by Dr Conradi and his colleagues fromHamburg,
Germany. I also want to thank the authors for providing me a copy
of their manuscript and the slides in advance.
The authors are to be congratulated for excellent outcomes in
a ‘‘real world’’ scenario outside the confines of a research trial
comparing 82 patients undergoing TAVI within the past year
with 82 propensity-matched surgical AVR patients over an 8- to
9-year period. In this group, the authors performed 62 transapical
and 22 transfemoral valve implantations, information that was not
shown in the slides but is in the manuscript that was given to me.
They noted a respectable overall mortality of 7.3% in the trans-
catheter group and 8.6% in the surgical AVR group. The stroke
rate was 2 patients, or 2.4%, in each group, and transfusion of
less than 1 unit of blood in the transcatheter group, which is excel-
lent. Overall, they have concluded similar results in short-term out-
comes of patients undergoing isolated AVR with an average
Society of Thoracic Surgeons predicted risk of mortality of
approximately 9%. So, again, congratulations are due for those
outcomes.
I have a couple of questions for the authors. First, you note the
paravalvular leak rate comparing the transcatheter valve and the
surgical valve group. Was there an associated morbidity and mor-
tality in those patients, especially in those that have a diminished
ejection fraction? Can you comment on the rate of paravalvular
leakage between the 2 groups?
Dr Conradi. Thank you, Dr Thourani, for those questions.
When looking at regurgitation rates, we found that about 50%ardiovascular Surgery c Volume 143, Number 1 69
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gree of paravalvular leakage. However, in the vast majority of
these patients, in 40 of those, this was trivial to mild and did not
have any clinical consequence. In only 1 patient was there a degree
of paravalvular regurgitation that was graded as moderate. In the
surgical group, we did not see any relevant paravalvular leakage.
The regurgitation that we saw here was central, as is known to oc-
cur with pericardial prostheses.
We did not see any influence on the outcome of these 82
patients.
Dr Thourani. We have had problems with patients who have
low ejection fractions, 20% to 25%. Even when we leave them
with mild aortic regurgitation, they continue to be admitted for
heart failure. It does not seem as though you have seen what we
have seen here in the United States at times.
Dr Conradi. In this cohort, we have not, but I can say that in
patients with pronounced cardiomyopathy, we tend to use the Cor-
eValve device (Medtronic, Inc, Minneapolis, Minn) rather than the
Edwards device because it does not need rapid ventricular pacing
for implantation. We believe that may be advantageous for the pa-
tient, to some extent, and maybe this is the bias that we have. As
a consequence, we do not see the effects that you are alluding to
in this particular cohort of patients receiving Edwards Sapien
valves.
Dr Thourani. It sounds like an interesting paper for next year’s
Association meeting.
Can you note the median valve size used in the surgical AVR
patients as compared with the TAVR patients? Have you seen
any outcome differences with patient–prosthesis mismatch, which
we have already heard about in the valve-in-valve from your site?
Dr Conradi. Thank you for the question. The mean size was
24 mm in the TAVI patients and 22 mm in the surgical patients.
There seems to be a difference, and it is indeed statistically sig-
nificant. However, these are 2 different valve types. If you con-
sider the technique of implantation, for example, a 23-mm TAVI
is not a 23-mm surgical valve. Furthermore, because you also
have to consider the extent of calcification present within the na-
tive valve and annulus, extension of the TAVI device may be dif-
ferent from patient to patient. Therefore, it is hard to draw
conclusions just by the manufacturer-given valve sizes that
were implanted.
Dr Thourani. In the manuscript, you report that a lot of your
patients have size 19 valves. Have you seen any major problems
from the surgical patients having only a 19-mm valve inserted?
Comparably, in the transcatheter patients the smallest valve was
23 mm. Is there any outcomes difference between the patients re-
ceiving 19-mm valves surgically versus the larger valve effective
orifice areas for the transcatheter patients?
Dr Conradi. From the 82 patients in the surgical cohort, 7 re-
ceived 19-mm valves. I do know that, maybe not from these partic-
ular 7 patients but in general from our experience, we did see the
same kind of problems that you were alluding to in our experience,
also. Whenever we can, we try to avoid these small prostheses, es-
pecially now with valve-in-valve technology being an option for
the future in these patients.
Dr Thourani.Although not discussed in your presentation, you
have not really broken out transapical or transfemoral techniques,
so you are putting thewhole transcatheter group into one. Are there70 The Journal of Thoracic and Cardiovascular Surgeany major differences between the transapical and transfemoral
approaches in the surgical AVR group?
Dr Conradi. Yes, we looked into that. The relation, as you
pointed out in the beginning, was 60 transapicals versus 22 trans-
femorals.We did not see amajor difference in this particular subset
of patients regarding outcome, even though the baseline character-
istics may have differed between the 2. We were surprised by that
finding at the beginning, but these are the facts and how we see
them.
Dr Thourani. I guess that leads to the question of what should
be chosen then. Somebody asked that earlier in the previous pre-
sentation. When a patient comes in, looking at your data and the
data presented from other people at this meeting, do you use
a transapical or a transfemoral approach or do you do a surgical
AVR, and how do you make that decision? I presume you are still
putting in surgical valves in patients. How do you make that differ-
entiation from Hamburg? What can we learn from you?
Dr Conradi.We have a transfemoral-first policy at our site, and
we have the same contraindications for that kind of approach as
many other investigators have. Severe peripheral artery disease
may preclude transfemoral access, as may small caliber vessels,
even though the XT device has somewhat diminished that hurdle.
Furthermore, we also look very closely at the aorta; tortuosity or
atherosclerosis or even aneurysm formation of the abdominal aorta
may be a problem, as is severe calcification of the aortic arch. All
in all, we have a pretty liberal stance on using transapical access.
DrMarc R. Moon (St Louis, Mo). You said you have a transfe-
moral-first approach. Is age then irrelevant at your institution?
Dr Conradi. Do you mean for the decision?
Dr Moon. If a 40-year-old patient comes in, does he or she get
a transfemoral-first approach?
Dr Conradi.No. I mean transfemoral first within the TAVI can-
didates. After deciding for TAVI, we have a transfemoral-first
policy.
Dr Moon. Since all your patients were at the same institution,
were you able to perform any cost data comparison?
Dr Conradi. We have a special situation in Germany. Reim-
bursement for TAVI is very high. It is possible that in other insti-
tutions this may be a reason for a TAVI or against surgery. I do
not know. With our approach, it certainly is not. We have the heart
team approach, and we look at each and every one of these patients
with our cardiology colleagues. For example, we would never use
age alone as a criterion for a TAVI or against surgery but rather re-
late that to the general status of the patient and comorbidities and
so on.
Dr Lucian Lozonschi (Madison, Wis). First, was this study
done with only the Edwards Sapien valve or were there any Core-
Valves also? It was not clear from your slides. Second, the mortal-
ity in both groups was high and actually higher than that reported
in the PARTNER trial in the surgical group. I have a question also,
regarding the paravalvular leak. You mentioned there was some
aortic regurgitation. We all know that aortic regurgitation is hard
to assess after TAVI, because there are multiple jets; there is a cen-
tral jet as well as paravalvular jets. And the data in the PARTNER
trial were rigorously checked by an independent core laboratory. In
the real-life situation, it is going to be hard to report how pleased
we are with ‘‘some’’ aortic regurgitation, and I think there may be
more patients with more than mild regurgitation than in yourry c January 2012
Conradi et al Acquired Cardiovascular Diseasegroup. I was struck by the low incidence of paravalvular leak, es-
pecially in the TAVI group. Can you comment, please?
Dr Conradi. Thank you for these important questions. The first
question was whether this was an Edwards-only cohort. As stated
on the methods slide, it was. These were 82 consecutive Edwards
patients. Within the same time frame, we did perform CoreValve
implantations, but these were not included in the study.
Regarding your comment about the PARTNER trial, I agree that
results were more favorable here in that trial. However, if you look
at the study design, there were important exclusion criteria forThe Journal of Thoracic and Cpatients in the PARTNER trial, such as severe heart failure or se-
vere renal insufficiency. We did not have any of these exclusion
criteria. This was a real world experience. If you compare our se-
ries to other series, like the Munich experience, other groups get
results similar to ours with this approach.
Regarding paravalvular leakage, you are completely right that
assessment of paravalvular leakage is not that easy, and grading
is not either. All of these patients were followed in our outpatient
clinic by our cardiology colleagues, and we have deep confidence
that they assess paravalvular leakages in a correct manner.ardiovascular Surgery c Volume 143, Number 1 71
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